에 대한 최신 뉴스 US Foods Hldg (NYSE:USFD) 주식

US Foods Hldg

Tyme Technologies

US Foods Holding Corp is the U.S. food service distributor. us Foods distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. In addition to its delivery business, the firm has 80 cash-and- carry stores under the Chef'Store banner. The company generates majority of the revenue from Meats and seafood products.

News

USFD

신선한 양파와 관련된 대장균(E. coli) 발생에 대응하여, 주요 미국 패스트푸드 체인인 맥도날드(NYSE:MCD), 레스토랑 브랜드 인터내셔널(NYSE:QSR) 그리고 얌 브랜즈(NYSE:YUM)가 메뉴에서 해당 채소를 제거하기로 결정했다. 이 사건으로 인해 49명이 병을 앓았고 한 명이 사망한 것으로 전해졌다.

쿼터 파운더 대장균 공포 속에 맥도날드의 라이벌 버거킹, 얌 브랜즈가 메뉴에서 양파 제거

Earnings

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

TRAK

VRAR

미국 주식 선물이 월요일 아침(현지 시간 기준)에 하락 거래되고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들은 다음과 같다: 1. 월스트리트는 카니발(NYSE:CCL)이 월요일 개장 전 매출 78억 3천만 달러, 주당 1.16달러의 분기 이익을 보고할 것으로 예상하고 있다. 카니발의 주가는 시간외 거래에서 1% 상승한 18.72달러를 기록했다.

월요일 주목해야 할 주식: 카니발, US 푸즈, 리포시트랙 그리고 2종목

BLBD

목요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:

목요일 주목해야 할 주식: 일라이 릴리, US 푸즈, 블루 버드 그리고 종목

US Foods Holding Corp

D. Boral Capital analyst Jason Kolbert maintains Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $29 price target.

Price Target

Analyst Ratings

IMNN

D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target

WIIM

AMPG

AmpliTech Group shares are trading lower after the company priced a $1.4 million registered direct offering at $0.92 per share.

Nano Nuclear Energy shares are trading lower after the company announced a $60 million private placement with three accredited institutional investors.

Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>).
GeminiBio has a 39-year history of supporting FBS customers. With this agreement, GeminiBio builds on these capabilities, by securing the manufacturing and global sales rights for Bio-Techne's R&amp;D Systems fetal bovine serum (FBS) product brands, Optima, Premium Select, and Premium. Following Bio-Techne's decision to discontinue their FBS products, GeminiBio worked closely with the company to create a seamless transition plan, ensuring continuous access to these high-quality FBS products for existing customers.

Asset Sales

TECH

Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum Product Rights And Inventory From Bio-Techne; No Financial Terms Disclosed

Biotech

General

LEXX

Lexaria Completes Dosing In Human Pilot Study #3 Investigating DehydraTECH-Processed Tirzepatide From Zepbound

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62cd59300ee57b0001a11a55/robert-cox">Goldman Sachs analyst Robert Cox</a> downgraded Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) from Buy to Neutral and maintained the price target of $313. Arthur J. Gallagher shares closed at $304.29 on Friday. <a href="https://www.benzinga.com/quote/AJG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup analyst Keith Horowitz downgraded the rating for M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from Buy to Neutral but raised the price target from $220 to $230. M&amp;T Bank shares closed at $221.12 on Friday. <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group analyst Joseph Feldman downgraded Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Outperform to Market Perform and lowered the price target from $102 to $95. Five Below shares closed at $86.92 on Friday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo analyst Stephen Baxter downgraded the rating for HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Equal-Weight to Underweight and slashed the price target from $400 to $320. HCA Healthcare shares closed at $324.93 on Friday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Tina Hou downgraded NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from Neutral to Sell and lowered the price target from $4.8 to $3.9. Nio shares closed at $4.84 on Friday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NIO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1010" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269.png" alt="" class="wp-image-663428" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269.png 1010w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269-768x457.png 768w" sizes="(max-width: 1010px) 100vw, 1010px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Downgrades

FIVE

This Nio Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

KODK

Kodak Retirement Income Plan Trust Sells $764.4M In Illiquid Assets To Mastercard Foundation For $550.6M Cash, Signs Additional Agreements For $87.3M Sale To Other Investors, Retaining $161.3M In Illiquid Assets And $917.2M In Hedge Fund Assets Pending Redemption Proceeds

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.

AVXL

D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Loop Capital analyst Alan Gould maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Hold and lowers the price target from $38 to $35.

Loop Capital Maintains Hold on Warner Music Gr, Lowers Price Target to $35

Dear Damon shareholders, supporters, reservation holders and enthusiasts,
I am deeply grateful for your steadfast support and dedication over the past two and half years – a period that has proven challenging for us all. Your belief in our mission has been a cornerstone of our perseverance during a time when many early-stage startups struggled to survive. You deserve a transparent account of the journey we have endured together and an understanding of the hurdles that has led us to where we are now, starting with a roadmap of what we need to do to get to production.
Path To Production, Explained
Currently with 15 in-house engineers, we are leveraging a combination of our employees alongside key subcontractors and external experts to advance development. Late-stage engineering is mostly complete, with vehicle mechanics 90% finalized. Power electronics are also 90% complete, with ongoing validation and the integration of key features. Similarly, mechanical and cooling systems are 90% complete, while the battery system is 70% complete, with efforts focused on the development of the cell interconnect system.
With adequate funding, the project is expected to progress to the pre-production stage,&nbsp;starting with validation and design confirmation, where we'll aim to make a run of pre-production prototypes and test them against our design requirements and regulations to confirm the designs before we release to tooling. Ordering all the tools to make our first run of parts from will be the next big milestone, subject to our ability to raise sufficient capital to make this substantial investment. This pre-production phase has an estimated completion of late 2025. The Production &amp; Commercialization Stage is expected to occur in parallel, focusing on the establishment of the final assembly and test facility at our HQ in San Rafael, CA, along with the development of distribution and delivery infrastructure. This stage is expected to conclude in 2026 and pending additional capital to achieve, serial production can then begin.
Commercial production is expected to commence after passing various internal and external tests and undergoing a self-certification process required for US-bound vehicle homologation. These tests include: the completion of Damon's ride quality and long-term durability testing, completion of FCC Title 47 certification for the onboard charger, completion of UN 38.3 battery testing, completion of Damon's internal battery testing, extreme temperature operation verification, brake testing per FMVSS, and an internal and external review of FMVSS compliance with our engineering subcontractor.
What Led Us Here
In the spring of 2022, Damon successfully raised a US$26M Series B financing, which marked the beginning of our efforts to raise a Series C round with the assistance of two major banks. This funding was intended to kickstart production. However, following the volatile SPAC era, the financial landscape shifted dramatically. The bursting of this bubble led to a severe downturn in the markets, and our efforts to secure a Series C production financing were unsuccessful. Despite these circumstances, the company was able to bridge itself with the support of various investors - enough to cover essential costs, having significantly reduced expenses across the board.
Navigating Funding Challenges
Since early 2022, inflation rates grew to reach 40-year highs, the highest level since 1981. Simultaneously. interest rates reached 20-year highs, rocking the financial markets and virtually wiping out risk capital for private companies, especially for pre-revenue startups in the capital-intensive automotive sector. Because of this, pre-revenue electric vehicle company valuations fell by an average 85%, and very few survived. Damon is an anomaly that persevered, despite how little risk capital had been available to fund the company's path to production. As previously noted, the company had undertaken multiple cost-cutting measures across all areas to navigate through these challenging past two years. These necessary reductions have regrettably led to significant delays. The journey has been far from easy, but these tough decisions were essential to ensure our continued operation and future success.
Nevertheless, we&nbsp;have persevered - a testament to everyone's faith and resilience when compared to many high-tech automotive startups that did not survive. And now that we are on the Nasdaq, the dream of reinventing motorcycling is far from over.
Going Public&nbsp;
After all this, it became evident that transitioning to the public markets was the best viable route to secure the necessary funding for production. In October 2023, we signed a merger agreement with Grafiti Holdings. Why did we choose Grafiti? &nbsp;It was the best merger partner we identified, possessing the ability to provide us with bridge financing and additional funding sources to help fund our Nasdaq preparation efforts and the benefit of no debt or liabilities.
During the 13-months it took to complete the merger and secure our Nasdaq listing, we faced what oftentimes seemed like insurmountable challenges. These included maintaining essential operations, keeping the remaining staff onboard, and managing increasing costs associated with going public. Additionally, we had to navigate the arduous, tax, audit and public listing requirements of both Canada and the US. These demands impacted our ability to fund production preparations, which are costly, thus extending our timeline to production.
Fast forward to now, and we achieved the goal of getting listed on the Nasdaq. Now, as a public company, we hope to gain access to the additional capital we need to fund our path to production. And this is why we need your continuing faith, your support and your confidence in us. Because we still have a lot of work ahead of us.

Damon CEO Pens Letter Providing Business Update And Outlining Production Roadmap

On Friday, the FDA approved BridgeBio Pharma, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42150289/attruby-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce-cardiovascular-deat" rel="noreferrer noopener">cardiovascular-related hospitalization</a>.
The FDA approval is based on ATTRibute-CM Phase 3 study results, which showed that Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42072773/bridgebio-pharmas-acoramidis-shows-competitive-edge-against-pfizers-tafamidisa-in-lucrative-but-competitive-attr-cm-market" rel="noreferrer noopener">BridgeBio Pharma&#8217;s Acoramidis Shows Competitive Edge Against Pfizer&#8217;s Tafamidisa In Lucrative But Competitive ATTR-CM Market</a>
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR.
Attruby was designed to mimic a naturally occurring &#8220;rescue mutation&#8221; of the TTR gene (T119M) that targets the root cause of ATTR-CM, the destabilization of the native TTR tetramer.
Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes.
The ATTRibute-CM Phase 3 study enrolled 632 participants with symptomatic ATTR-CM associated with either wild-type or variant TTR.
BridgeBio submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025.
BridgeBio has granted&nbsp;Bayer AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>)&nbsp;exclusive rights to commercialize acoramidis for ATTR-CM in Europe.
The company said it will provide Attruby for free to patients who participated in the trial.
William Blair writes, &#8220;We continue to view a reduction in all-cause mortality on label as a necessary distinction to gain major market share in ATTR-CM alongside Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) tafamidis.&#8221;
Since the Attruby label doesn&#8217;t include data on overall mortality, the William Blair analyst notes Pfizer might shift its marketing focus to emphasize claims about mortality benefits.
Price Action: BBIO stock is up 24.3% at $29.10 during the premarket session at last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/11/42162996/vertical-aerospace-soars-50-million-funding-boost-and-debt-conversion-propel-evtol-maker-forward" target="_blank" rel="noreferrer noopener">Vertical Aerospace Soars: $50 Million Funding Boost And Debt Conversion Propel eVTOL Maker Forward</a></li>
</ul>

Analyst Color

Equities

Health Care

Movers

BAYRY

BBIO

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.januxrx.com%2F&amp;esheet=54157214&amp;newsitemid=20241125381273&amp;lan=en-US&amp;anchor=Janux+Therapeutics%2C+Inc.&amp;index=1&amp;md5=e257bbb56600d7291454ec697d3b55f8">Janux Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event on Monday, December 2, 2024, at 4:30 PM ET.
David Campbell, Ph.D., President &amp; Chief Executive Officer, will provide an update on JANX007 Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).

JANX

Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In mCRPC And Doses Selected For Phase 1b Expansion Studies

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Office Properties Income Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>)</h3>
<ul>
<li>On Oct. 30, Office Properties IT reported worse-than-expected third-quarter FFO results. The company's stock fell around 40% over the past month and has a <a href="https://www.benzinga.com/quote/OPI">52-week low of $1.06</a>.</li>
<li>RSI Value: 20.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OPI Price Action: Shares of Office Properties Income Trust closed at $1.14 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">latest OPI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261.png" alt="" class="wp-image-662916" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041017/image-261-768x701.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul>
<li>On Nov. 15, Wheeler Real Estate Investment Trust announced a 1-for-2 reverse stock split effective Nov. 18. The company's stock fell around 32% over the past five days and <a href="https://www.benzinga.com/quote/WHLR">has a 52-week low</a> of $5.79.</li>
<li>RSI Value: 26.03</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust fell 2.2% to close at $8.50 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">trend in WHLR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262.png" alt="" class="wp-image-662917" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041125/image-262-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Creative Media &amp; Community Trust Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>)</h3>
<ul>
<li>On Nov. 8, Creative Media reported a quarterly loss of $1.22 per share which missed the analyst consensus estimate of a loss of 64 cents per share. &#8220;We continue to make progress on our previously announced actions to accelerate our focus towards premier multifamily assets, strengthen our balance sheet and improve our liquidity,&#8221; said David Thompson, Chief Executive Officer of Creative Media &amp; Community Trust Corporation. The company's stock fell around 25% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/CMCT">low of $0.21.</a></li>
<li>RSI Value: 21.55</li>
<li>CMCT Price Action: Shares of Creative Media &amp; Community Trust fell 9.1% to close at $0.22 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">breakout in CMCT shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263.png" alt="" class="wp-image-662923" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25041229/image-263-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

CMCT

WHLR

Top 3 Real Estate Stocks That May Explode In Q4

icometrix' FDA-cleared quantitative brain solution for neurological conditions including Alzheimer's and multiple sclerosis is seamlessly integrated into Philips next generation BlueSeal MR scanners, and will be deployed in its comprehensive informatics platform &nbsp;

Events

Philips And Icometrix Report Results Of MRI Brain Scans To Optimize Alzheimer And Multiple Sclerosis Diagnosis At RSNA 2024

Telsey Advisory Group analyst Dana Telsey maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Outperform and maintains $42 price target.

BBWI

Telsey Advisory Group Maintains Outperform on Bath & Body Works, Maintains $42 Price Target

Partnership enhances gift card shopping experience with quick local deliveries from DashMart and other popular merchants within the DoorDash app
ATLANTA, Nov. 25, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310547-1&amp;h=4183263924&amp;u=https%3A%2F%2Fwww.incomm.com%2F&amp;a=InComm+Payments">InComm Payments</a>, a global payments technology company, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310547-1&amp;h=4056120216&amp;u=https%3A%2F%2Fwww.doordash.com%2F&amp;a=DoorDash">DoorDash</a>, the premier local commerce platform, today announced a partnership enabling consumers to browse, purchase and order delivery of gift cards for hundreds of merchants within the DoorDash app. The offering will launch on Friday, Nov. 29, with promotions beginning on Black Friday that offer&nbsp;limited-time discounts on select digital gift card orders made through the app or website&#x2A; by eligible customers.

DASH

DoorDash Selects InComm Payments As Partner To Launch In-App Gift Card Shopping Experience

Loop Capital analyst Jeffrey Stevenson maintains GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) with a Hold and raises the price target from $85 to $93.

Loop Capital Maintains Hold on GMS, Raises Price Target to $93

Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Nutanix to report an earnings per share (EPS) of $0.30.
The announcement from Nutanix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 20.31% increase in the share price on the subsequent day.
Here's a look at Nutanix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.16</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.28</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Price Change %</td>
<td>20.0%</td>
<td>-23.0%</td>
<td>7.000000000000001%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732543326_0.png" alt="eps graph" />
<h3>Performance of Nutanix Shares</h3>
Shares of Nutanix were trading at $73.18 as of November 22. Over the last 52-week period, shares are up 80.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NTNX/earnings">To track all earnings releases for Nutanix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTNX

What to Expect from Nutanix's Earnings

Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) will release its quarterly earnings report on Tuesday, 2024-11-26. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Nordstrom to report an earnings per share (EPS) of $0.22.
Nordstrom bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.25 in the last quarter, leading to a 4.21% increase in the share price on the following day.
Here's a look at Nordstrom's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.71</td>
<td>-0.07</td>
<td>0.88</td>
<td>0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.96</td>
<td>-0.24</td>
<td>0.96</td>
<td>0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>5.0%</td>
<td>-16.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732543318_0.png" alt="eps graph" />
<h3>Market Performance of Nordstrom's Stock</h3>
Shares of Nordstrom were trading at $23.24 as of November 22. Over the last 52-week period, shares are up 51.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Nordstrom</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Nordstrom.
The consensus rating for Nordstrom is Neutral, derived from 9 analyst ratings. An average one-year price target of $22.44 implies a potential 3.44% downside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Ollie's Bargain Outlet, Kohl's and Savers Value Village, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Ollie's Bargain Outlet is favoring an Outperform trajectory, with an average 1-year price target of $106.12, suggesting a potential 356.63% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Kohl's, with an average 1-year price target of $21.0, implying a potential 9.64% downside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Savers Value Village, with an average 1-year price target of $10.0, indicating a potential 56.97% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Ollie's Bargain Outlet, Kohl's and Savers Value Village, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nordstrom</td>
<td>Neutral</td>
<td>3.23%</td>
<td>$1.49B</td>
<td>13.68%</td>
</tr>
<tr>
<td>Ollie's Bargain Outlet</td>
<td>Outperform</td>
<td>12.41%</td>
<td>$219.03M</td>
<td>3.14%</td>
</tr>
<tr>
<td>Kohl's</td>
<td>Neutral</td>
<td>-4.18%</td>
<td>$1.60B</td>
<td>1.73%</td>
</tr>
<tr>
<td>Savers Value Village</td>
<td>Neutral</td>
<td>0.53%</td>
<td>$224.02M</td>
<td>5.09%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nordstrom ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. Nordstrom is at the top for gross profit. For return on equity, Nordstrom is in the middle compared to its peers.
<h3>Discovering Nordstrom: A Closer Look</h3>
Nordstrom is a fashion retailer that operates about 93 department stores and more than 260 off-price Nordstrom Rack stores. The company also operates both full- and off-price e-commerce sites, two clearance stores, and seven Local locations. Nordstrom's largest merchandise categories are women's apparel (27% of 2023 sales), shoes (26% of 2023 sales), men's apparel (15% of 2023 sales), and beauty (13% of 2023 sales). Nordstrom, which traces its history to a shoe store opened in Seattle in 1901, continues to be partially owned and managed by members of the eponymous family.
<h3>Nordstrom's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Nordstrom's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.23% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Nordstrom's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.13%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nordstrom's ROE stands out, surpassing industry averages. With an impressive ROE of 13.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.43%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 4.46, Nordstrom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/JWN/earnings">To track all earnings releases for Nordstrom visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Nordstrom's Quarterly Earnings

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.elastic.co%2F&amp;esheet=54157245&amp;newsitemid=20241125938547&amp;lan=en-US&amp;anchor=Elastic&amp;index=1&amp;md5=e528425de165a4f8983fc7a63ab6b7b4">Elastic</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>), the Search AI Company, announced today it is strengthening its relationship with Amazon Web Services (AWS) by leveraging the latest generative artificial intelligence (AI) services from AWS. As part of this collaboration, Elastic is offering large language model (LLM) observability support for Amazon Bedrock in Elastic Observability. Amazon Bedrock is a fully managed service that offers a choice of high-performing foundation models (FMs) from leading AI companies via a single API, along with a broad set of capabilities organizations need to build generative AI applications with security, privacy, and responsible AI.
The new integration offers Site Reliability Engineers (SREs) detailed insights into their Amazon Bedrock LLMs performance and usage. SREs can now leverage Elastic Observability to monitor invocations, errors, and latency metrics. This allows them to more proactively prevent incidents and identify root causes, ensuring optimal performance for their Amazon Bedrock-powered generative AI applications. Additionally, Elastic AI Assistant, which utilizes Amazon Bedrock, helps SREs accurately analyze data, generate visualizations, and provides actionable recommendations for issue resolution.

ESTC

Elastic Now Collaborates With AWS To Leverage Generative AI Capabilities; Elastic Is Offering Large Language Model Observability Support For Amazon Bedrock In Elastic Observability

Get caught up quickly on the top news and calls moving stocks with these

Qualcomm, Moderna report quarterly beats: Morning Buzz

U.S. Foods Holding Corp (USFD) Q3 2024 Earnings Call Transcript

Us Foods Holding Corp. ( ($USFD) ) has released its Q3 earnings. Here is a breakdown of the information Us Foods Holding Corp. presented to its inv...

US Foods Reports Strong Q3 Earnings Amid Challenges

Analysts have been eager to weigh in on the Consumer Goods sector with new ratings on WK Kellogg Co (KLG – Research Report) and US Foods Holding (U...

Analysts Offer Insights on Consumer Goods Companies: WK Kellogg Co (KLG) and US Foods Holding (USFD)

Brian Harbour, an analyst from Morgan Stanley, maintained the Buy rating on US Foods Holding (USFD – Research Report). The associated price target ...

US Foods Holding: Strong Cost Management and Profit Improvement Drive Buy Rating

BTIG raised the firm's price target on US Foods (USFD) to $76 from $72 and keeps a Buy rating on the shares after its Q3 earnings beat. Hurricanes ...

US Foods price target raised to $76 from $72 at BTIG

BMO Capital raised the firm's price target on US Foods (USFD) to $75 from $62 and keeps an Outperform rating on the shares. The company posted a st...

US Foods price target raised to $75 from $62 at BMO Capital

Piper Sandler analyst Brian Mullan raised the firm's price target on US Foods (USFD) to $75 from $61 and keeps an Overweight rating on the shares f...

US Foods price target raised to $75 from $61 at Piper Sandler

B&G Foods gets insider-buying bump

United Natural Foods: Still Tasty As Earnings Near Based On Improving Guidance

AMZN

ANDE

BROS

COMM

DLTR

DUOL

FRSH

GOEV

MRNA

NSANF

NSANY

PFGC

PLTR

QCOM

SEDG

SPTN

SRPT

TTWO

UNFI

WOLF

Press Releases

US Foods, Feeding America® to Shape the Future of Food Access With Expansion of Innovative Direct to Neighbor Locker Project

Imperial Dade Announces Appointment of Fareed Khan as Chief Financial Officer

US Foods Fall Scoop Product Lineup Targets Operator Pain Points

US Foods Announces Private Offering of $500 Million of Senior Unsecured Notes

US Foods Announces Pricing of Private Offering of $500 Million of Senior Unsecured Notes

US Foods 2024 Diner Dispatch Survey Uncovers Surprising Shifts in Diner Preferences

US Foods to Host Third Quarter 2024 Financial Results Conference Call and Webcast

US Foods Reports Third Quarter Fiscal Year 2024 Earnings

US Foods Names First National Class of US Foods Scholars to Fuel Culinary Talent Pipeline for Operators

US Foods to Present at the 2024 Morgan Stanley Global Consumer & Retail Conference

Andersons

The Chefs' Warehouse, Inc. - Common Stock

Chefs' Warehouse

Davis Commodities Limited - Ordinary Shares

Davis Commodities

HF Foods Group

Performance Food Group Company Common Stock

Performance Food Gr

SpartanNash

Sysco

United Natural Foods

Piper Sandler

Barclays

JP Morgan

Truist Securities

신선한 양파와 관련된 대장균(E. coli) 발생에 대응하여, 주요 미국 패스트푸드 체인인 맥도날드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), 레스토랑 브랜드 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) 그리고 얌 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>)가 메뉴에서 해당 채소를 제거하기로 결정했다. 이 사건으로 인해 49명이 병을 앓았고 한 명이 사망한 것으로 전해졌다.
무슨 일이 (What Happened): 로이터에 따르면, 버거킹의 모회사인 레스토랑 브랜드 인터내셔널과 얌 브랜즈도 신선한 양파를 메뉴에서 제외하기로 결정했다. 한 대변인은 약 5%의 버거킹 매장이 이미 이 변경을 실시했다고 확인했다.
이 보도에 따르면 콜로라도주 롱몬트 버거킹의 매니저 마리아 곤잘레스(Maria Gonzales)는 &#8220;앞으로 당분간 양파를 전혀 사용하지 말라는 회사 측의 지시를 받았다&#8221;고 말했다.
맥도날드는 오염된 양파의 출처가 테일러 팜스(Taylor Farms)임을 확인했으며 현재 리콜되었다. 미국의 주요 식품 서비스 공급업체인 US 푸즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>)의 메모에 따르면 콜로라도 시설의 노란 양파가 회수되었다.
미국 식품의약국(FDA)는 영향을 받은 맥도날드 매장들의 공급업체는 테일러 팜스라고 발표하고 리콜을 시작했다고 전했다. 이 건강 규제 당국은 연방 및 주 당국과 회사들과 협력하여 양파가 발생의 원인인지 확인하고 있다.
왜 중요한가 (Why It Matters): 이번 발생은 맥도날드 햄버거와 연관된 대장균 사례가 최근에 보고된 후 발생한 일로, 이로 인해 이 <a href="https://www.benzinga.com/news/24/10/41494285/mcdonalds-stock-is-tumbling-wednesday-heres-why">회사의 주가가 하락</a>한 바 있다. 미국 질병통제예방센터(CDC)는 10개 주에서 49건의 대장균 감염 사례가 확인되었으며, 대부분의 환자들이 McDonald's의 쿼터 파운더(Quarter Pounder) 햄버거를 먹었다고 보고했다.
FDA는 여러 사람이 맥도날드의 쿼터 파운더와 관련된 대장균으로 아프게 된 후 테일러 팜스에 대한 <a href="https://www.benzinga.com/news/24/10/41527681/fda-launches-investigation-into-mcdonalds-supplier-taylor-farms-following-e-coli-outbreak">조사</a>를 시작했다. FDA는 현재 맥도날드 햄버거에 제공된 슬라이스 양파가 오염의 가장 가능성이 높은 원인이라고 생각하고 있다.
발생에도 불구하고, 애널리스트들은 이전에 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41494741/mcdonalds-well-positioned-to-contain-e-coli-outbreak-analysts-say-impact-minimal-co">맥도날드 주식에 미치는 영향이 미미할 것</a>이라고 언급했다. 그러나 베어드 에퀴티 리서치(Baird Equity Research)의 애널리스트 데이비드 타란티노(David Tarantino)는 소비자 심리에 대한 우려로 수요일 늦게 맥도날드의 주가를 &#8216;중립&#8217;으로 하향 조정했다.
가격 움직임: 목요일, 맥도날드 주식은 정규 거래에서 1% 상승하여 $301.58에 마감되었으며, 이후 시간외 거래에서는 0.12% 추가 상승하였다.
다음 읽을 내용: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41459673/whats-going-on-with-trump-media-technology-stock-today?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">트럼프 미디어 &amp; 기술 주식에 무슨 일이 일어나고 있나요?</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.

미국 주식 선물이 월요일 아침(현지 시간 기준)에 하락 거래되고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들은 다음과 같다:
1. 월스트리트는 카니발(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>)이 월요일 개장 전 매출 78억 3천만 달러, 주당 1.16달러의 분기 이익을 보고할 것으로 예상하고 있다. 카니발의 주가는 시간외 거래에서 1% 상승한 18.72달러를 기록했다.
2. US 푸즈 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>)가 5억 달러의 무담보 선순위 채권 사모 발행 가격을 발표했다. US 푸즈의 주식은 애프터 마켓에서 2.2% 오른 61.49달러로 거래되었다.
3. 애널리스트들은 리포시트랙(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>) 최신 분기에 1주당 6센트의 이익과 507만 달러의 매출을 기록할 것으로 예상하고 있다. 이 회사는 시장이 마감된 후에 실적을 발표할 예정이다. 리포시트랙의 주식은 애프터 마켓에서 0.1% 오른 17.72달러로 거래되었다.
여기에서 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하십시오.
4. 에스페이 매뉴펙처링 &amp; 일렉트로닉스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESP#NYSE">ESP</a>)는 4분기 주당 73센트의 이익을 기록했으며, 이는 작년 동기 36센트에서 증가한 수치이다. 매출은 834만 달러에서 1,161만 달러로 증가했다. 에스페이의 주식은 애프터 마켓에서 9.6% 상승한 27.20달러로 거래되었다.
5. 애널리스트들은 글림스 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>)가 시장 마감 후에 1주당 8센트의 분기 손실과 200만 달러의 매출을 기록할 것으로 예상하고 있다. 글림스 그룹의 주식은 애프터 마켓에서 3.3% 하락한 0.77달러로 거래되었다.
다음 확인하세요:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">3분기에 폭락할 수 있는 상위 4개 소재 주식</a></li>
</ul>
사진 제공: Pixabay

목요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
<ul>
<li>월스트리트는 일라이 릴리 앤드 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)가 개장 전 매출 99억 5천만 달러, 주당 2.70달러의 분기 이익을 보고할 것으로 예상한다. 일라이 릴리의 주가는 시간외 거래에서 0.9% 하락한 765.32달러를 기록했다.</li>
<li></li>
<li>블루 버드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>)는 예상보다 나은 3분기 재무 실적을 보고하고 새 CEO를 발표했다. 블루버드 주가는 시간외 거래에서 5.3% 상승한 51.00달러를 기록했다.</li>
<li></li>
<li>분석가들은 US 푸즈 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>)이 96억 4천만 달러의 매출과 주당 93센트의 분기 이익을 발표할 것으로 예상하고 있다. 회사는 시장이 열리기 전에 실적을 발표할 예정이다. US 푸즈의 주가는 시간외 거래에서 0.2% 상승한 51.20달러를 기록했다.</li>
<li></li>
<li>아웃셋 메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>)는 예상보다 나쁜 2분기 재무 결과를 보고하고 FY24 매출 지침을 하향 조정했다. 아웃셋 메디컬의 주가는 시간외 거래에서 39.7% 하락한 2.05달러를 기록했다.</li>
<li></li>
<li>분석가들은 파커 하니핀(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>)이 개장 전 매출 50억 8천만 달러, 주당 6.22달러의 분기 이익을 발표할 것으로 예상한다. 파커 하니핀의 주가는 수요일 1.1% 하락한 512.50달러로 마감했다.</li>
<li></li>
</ul>
Photo courtesy: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

목요일 아침 (현지 시간) 미국 주식 선물이 하락세로 거래되면서 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다:
<ul>
<li>월스트리트는 로블록스 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>)가 개장 전 주당 53센트의 분기 손실과 9억 2,200만 달러의 매출을 보고할 것으로 예상하고 있다. 로블록스의 주식은 시간외 거래에서 0.7% 상승한 39.30달러를 기록했다.</li>
<li>줌인포 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NYSE">ZI</a>)는 긍정적인 1분기 실적을 발표했지만, 2분기 전망은 예상보다 약했다. 이 회사는 2분기 EPS가 주당 25센트 추정치보다 23센트~24센트 범위에 있을 것으로 예상하고 있다. 2분기 매출은 추정치 3억 1,311만 달러 대비 3억 600만~3억 900만 달러로 예상된다. 줌인포의 주식은 시간외 거래에서 0.4% 상승한 12.19달러에 거래되었다</li>
<li>애널리스트들은 US 푸즈 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>)가 분기당 주당 53센트의 이익과 89억 2,000만 달러의 매출을 발표할 것으로 예상하고 있다. 이 회사는 개장 전에 분기 실적을 발표할 것이다. US 푸즈의 주식은 시간외 거래에서 1.4% 상승한 53.10달러에 거래됐다.</li>
</ul>
이곳에서 <a href="https://www.benzinga.com/premarket/">개장 전 시황 개요를 확인하세요</a>
<ul>
<li>비욘드 미트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>)가 1분기에 예상보다 큰 손실을 기록했다. 이 회사는 2분기 매출이 8,500만 달러에서 9,000만 달러 사이일 것으로 예상하고 있으며, 2024년의 전체 매출은 3억 1,500만 달러에서 3억 4,500만 달러 사이로 예상하고 있다. 비욘드 미트의 주식은 시간외 거래에서 13.5% 하락한 7.10달러에 거래되었다.</li>
<li>애널리스트들은 H&amp;R 블록(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>)가 시장 마감 후 주당 4.62달러의 분기 이익과 214억 달러의 분기 매출을 발표할 것으로 예상하고 있다. H&amp;R 블록의 주식은 시간외 거래에서 0.9% 상승한 48.95달러에 거래됐다.</li>
</ul>

Comments

US Foods Hldg

뉴스

에 대한 최신 뉴스 US Foods Hldg (NYSE:USFD) 주식

금요일, 10월 25, 2024

월요일, 9월 30, 2024

목요일, 8월 08, 2024

목요일, 5월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌